Succinobuccol, an investigational monosuccinic acid ester of probucol, was not associated with a reduction in a composite end point of major cardiovascular events in patients diagnosed with acute coronary syndrome (ACS), but use of the agent did result in improvements on certain secondary end points.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

From the 56th Annual Scientific Session of the American College of Cardiology: ARISE: Succinobucol delivers mixed results in phase 3 trial of patients with ACS

Newsletter